Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines - PubMed (original) (raw)
Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines
C M Wischik et al. Proc Natl Acad Sci U S A. 1996.
Abstract
In Alzheimer disease (AD) the microtubule-associated protein tau is redistributed exponentially into paired helical filaments (PHFs) forming neurofibrillary tangles, which correlate with pyramidal cell destruction and dementia. Amorphous neuronal deposits and PHFs in AD are characterized by aggregation through the repeat domain and C-terminal truncation at Glu-391 by endogenous proteases. We show that a similar proteolytically stable complex can be generated in vitro following the self-aggregation of tau protein through a high-affinity binding site in the repeat domain. Once started, tau capture can be propagated by seeding the further accumulation of truncated tau in the presence of proteases. We have identified a nonneuroleptic phenothiazine previously used in man (methylene blue, MB), which reverses the proteolytic stability of protease-resistant PHFs by blocking the tau-tau binding interaction through the repeat domain. Although MB is inhibitory at a higher concentration than may be achieved clinically, the tau-tau binding assay was used to identify desmethyl derivatives of MB that have Ki values in the nanomolar range. Neuroleptic phenothiazines are inactive. Tau aggregation inhibitors do not affect the tau-tubulin interaction, which also occurs through the repeat domain. Our findings demonstrate that biologically selective pharmaceutical agents could be developed to facilitate the proteolytic degradation of tau aggregates and prevent the further propagation of tau capture in AD.
Similar articles
- Cellular Models of Aggregation-dependent Template-directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer Disease.
Harrington CR, Storey JM, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP, Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM. Harrington CR, et al. J Biol Chem. 2015 Apr 24;290(17):10862-75. doi: 10.1074/jbc.M114.616029. Epub 2015 Mar 10. J Biol Chem. 2015. PMID: 25759392 Free PMC article. - Staging the pathological assembly of truncated tau protein into paired helical filaments in Alzheimer's disease.
Mena R, Edwards PC, Harrington CR, Mukaetova-Ladinska EB, Wischik CM. Mena R, et al. Acta Neuropathol. 1996;91(6):633-41. doi: 10.1007/s004010050477. Acta Neuropathol. 1996. PMID: 8781663 - Immunological characterization of the region of tau protein that is bound to Alzheimer paired helical filaments.
Caputo CB, Wischik C, Novak M, Scott CW, Brunner WF, De Garcini EM, Lo MM, Norris TE, Salama AI. Caputo CB, et al. Neurobiol Aging. 1992 Mar-Apr;13(2):267-74. doi: 10.1016/0197-4580(92)90039-z. Neurobiol Aging. 1992. PMID: 1381814 - The role of tau oligomers in the onset of Alzheimer's disease neuropathology.
Cárdenas-Aguayo Mdel C, Gómez-Virgilio L, DeRosa S, Meraz-Ríos MA. Cárdenas-Aguayo Mdel C, et al. ACS Chem Neurosci. 2014 Dec 17;5(12):1178-91. doi: 10.1021/cn500148z. Epub 2014 Oct 15. ACS Chem Neurosci. 2014. PMID: 25268947 Review. - Modeling Prion-Like Processing of Tau Protein in Alzheimer's Disease for Pharmaceutical Development.
Wischik CM, Schelter BO, Wischik DJ, Storey JMD, Harrington CR. Wischik CM, et al. J Alzheimers Dis. 2018;62(3):1287-1303. doi: 10.3233/JAD-170727. J Alzheimers Dis. 2018. PMID: 29226873 Free PMC article. Review.
Cited by
- Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models.
Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, Goatman K, Goatman EA, Deiana S, Close SP, Zabke C, Stamer K, Dietze S, Schwab K, Storey JM, Harrington CR, Wischik CM, Theuring F, Riedel G. Melis V, et al. Behav Pharmacol. 2015 Jun;26(4):353-68. doi: 10.1097/FBP.0000000000000133. Behav Pharmacol. 2015. PMID: 25769090 Free PMC article. - Paired Helical Filament-Forming Region of Tau (297-391) Influences Endogenous Tau Protein and Accumulates in Acidic Compartments in Human Neuronal Cells.
Pollack SJ, Trigg J, Khanom T, Biasetti L, Marshall KE, Al-Hilaly YK, Rickard JE, Harrington CR, Wischik CM, Serpell LC. Pollack SJ, et al. J Mol Biol. 2020 Aug 7;432(17):4891-4907. doi: 10.1016/j.jmb.2020.05.027. Epub 2020 Jul 16. J Mol Biol. 2020. PMID: 32681841 Free PMC article. - The Potential of Indole/Indolylquinoline Compounds in Tau Misfolding Reduction by Enhancement of HSPB1.
Chang KH, Lin CH, Chen HC, Huang HY, Chen SL, Lin TH, Ramesh C, Huang CC, Fung HC, Wu YR, Huang HJ, Lee-Chen GJ, Hsieh-Li HM, Yao CF. Chang KH, et al. CNS Neurosci Ther. 2017 Jan;23(1):45-56. doi: 10.1111/cns.12592. Epub 2016 Jul 18. CNS Neurosci Ther. 2017. PMID: 27424519 Free PMC article. - Targeting Hsp70 facilitated protein quality control for treatment of polyglutamine diseases.
Davis AK, Pratt WB, Lieberman AP, Osawa Y. Davis AK, et al. Cell Mol Life Sci. 2020 Mar;77(6):977-996. doi: 10.1007/s00018-019-03302-2. Epub 2019 Sep 24. Cell Mol Life Sci. 2020. PMID: 31552448 Free PMC article. Review. - Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation.
Ballatore C, Brunden KR, Piscitelli F, James MJ, Crowe A, Yao Y, Hyde E, Trojanowski JQ, Lee VM, Smith AB 3rd. Ballatore C, et al. J Med Chem. 2010 May 13;53(9):3739-47. doi: 10.1021/jm100138f. J Med Chem. 2010. PMID: 20392114 Free PMC article.
References
- J Pharm Sci. 1972 Jul;61(7):1086-90 - PubMed
- Acta Neuropathol. 1996;91(6):633-41 - PubMed
- J Cell Biol. 1985 Jun;100(6):1905-12 - PubMed
- EMBO J. 1985 Dec 30;4(13B):3661-5 - PubMed
- Biol Psychiatry. 1986 Aug;21(10):915-20 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous